Association between substance use problems and health outcomes among HIV-positive patients in NYC
Methods: This retrospective cohort study includes electronic medical records (EMRs) of 5,584 HIV-1-infected patients who attended comprehensive care clinics in NYC in 2012. EMRs were used to assess the prevalence of medical conditions among HIV-positive patients with medically documented ADU problems.
Results: Patients who had either an alcohol (11%) or a drug-use (32%) problem were found to be at increased risk for respiratory infections, tuberculosis and bacterial infections, viral hepatitis, renal disease and other alcohol-related complications, cardiovascular disease, blood disorders, cancer diagnosis, and nutritional deficiency compared to those who did not (all p < .001). In logistic regression analyses adjusted for age, race/ethnicity, CD4 cell count, having an undetectable viral load, the risk odds of being diagnosed with three or more medical conditions among those with both ADU problems (9%) was about 4.3 times (95% CI 3.49 to 5.39; p < .001) of that for those without any ADU problems (65%). Patients with ADU problems had higher odds as well when compared to those with only alcohol (3%) or only drug-use (23%) problems.
Conclusions: HIV-positive patients with co-occurring alcohol and drug-use problems are at increased risk for medical comorbidities. These findings suggest that comprehensive approaches that integrate ways to address ADU problems are needed for HIV-infected patients.
Learning Areas:Public health or related research
Social and behavioral sciences
Describe the association between substance use and health in HIV-positive patients in NYC Discuss implications for behavioral interventions to improve HIV-related health outcomes among HIV-positive individuals
Keyword(s): HIV/AIDS, Alcohol Use
Qualified on the content I am responsible for because: I am a Co-Investigator on this study and have been conducting HIV-related research for over a decade.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.